PTPRC and acute myeloid leukemia: To corroborate that cytotoxicity was due to active targeting of anti-B220 MSNs containing DN (MSN-DN) to B220+ AML LSCs, followed by cellular uptake and intracellular release of DN, B220 antigen was blocked on B220+ AML LSCs.